| Literature DB >> 28672780 |
Baozhen Wang1, Uichi Akiba2, Jun-Ichi Anzai3.
Abstract
This article reviews recent progress in the development of nanomaterial-based electrochemical biosensors for cancer biomarkers. Because of their high electrical conductivity, high affinity to biomolecules, and high surface area-to-weight ratios, nanomaterials, including metal nanoparticles, carbon nanotubes, and graphene, have been used for fabricating electrochemical biosensors. Electrodes are often coated with nanomaterials to increase the effective surface area of the electrodes and immobilize a large number of biomolecules such as enzymes and antibodies. Alternatively, nanomaterials are used as signaling labels for increasing the output signals of cancer biomarker sensors, in which nanomaterials are conjugated with secondary antibodies and redox compounds. According to this strategy, a variety of biosensors have been developed for detecting cancer biomarkers. Recent studies show that using nanomaterials is highly advantageous in preparing high-performance biosensors for detecting lower levels of cancer biomarkers. This review focuses mainly on the protocols for using nanomaterials to construct cancer biomarker sensors and the performance characteristics of the sensors. Recent trends in the development of cancer biomarker sensors are discussed according to the nanomaterials used.Entities:
Keywords: biosensor; cancer biomarker; carbon nanotube; graphene; metal nanoparticle
Mesh:
Substances:
Year: 2017 PMID: 28672780 PMCID: PMC6152304 DOI: 10.3390/molecules22071048
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Use of nanomaterials as a surface modifier (A) and as a signaling label (B) in constructing electrochemical biosensors for cancer biomarkers.
Figure 2Protocol for preparing epidermal growth factor receptor (EGFR) sensors through stepwise deposition of cysteamine, p-phenyldiisothiocyanate (PDITC), protein G, and anti-EGFR on a gold nanoparticle (AuNP)-modified electrode. Reprinted with permission from [33]. Copyright 2013, Elsevier.
Figure 3Deposition of as-prepared AuNPs on a glassy carbon (GC) electrode (GCE) for preparing the carcinoembryonic antigen (CEA) immunosensor. Reprinted with permission from [36]. Copyright 2012, Elsevier.
Figure 4Preparation of the CEA immunosensor with Ag nanoparticles modified with a secondary antibody and glucose oxidase (GOx) as a signaling label. Reprinted with permission from [54]. Copyright 2015, Elsevier.
Figure 5Calibration graph for the CEA sensor (A) and differential pulse voltammetry (DPV) (B). Reprinted with permission from [54]. Copyright 2015, Elsevier.
Metal nanoparticle-based biosensors for cancer biomarkers.
| Nanomaterials Used | Electrode | Transduction Method | Analyte | Detection Range | LOD | Ref. |
|---|---|---|---|---|---|---|
| protein A/AuNPs | GCE | voltammetry | AFP | 5–80 ng mL−1 | 3.7 ng mL−1 | [ |
| protein G/AuNPs | AuE | voltammetry | AFP | 0.005–0.2 ng mL−1 | 2 pg mL−1 | [ |
| protein G/AuNPs | AuE | impedimetry | EGFR | 0.001–1000 ng mL−1 | 0.34 pg mL−1 | [ |
| ferrocene/AuNPs | GCE | voltammetry | PSA | 0.002–10 ng mL−1 | 0.5 pg mL−1 | [ |
| DNA/AuNPs | GCE | impedimetry | BRCA1 | 50 fM–1 nM | 1.72 fM | [ |
| AuNPs | GCE | voltammetry | CEA | 10 fg mL−1–100 ng mL−1 | 3 fg mL−1 | [ |
| AuNPs | ITO | impedimetry | HSP70 | 1–166 fg mL−1 | 0.0618 fg mL−1 | [ |
| glutathione/AuNPs | SPCE | amperometry | IL-6 | 0.3–20 pg mL−1 | 0.3 pg mL−1 | [ |
| glutathione/AuNPs | SPCE | amperometry | PSA | 0.225–5 pg·mL−1 | 0.1 pg mL−1 | [ |
| graphene/AuNPs | ITO | amperometry | IL-6 | 1–40 pg mL−1 | 0.3 pg mL−1 | [ |
| Th/PDA/GO/AuNPs | GCE | voltammetry | AFP | 0.1–150 ng mL−1 | 0.03 ng mL−1 | [ |
| CdSe/silica/AuNPs | AuE | impedimetry | CA-125 | 0–0.1 U mL−1 | 0.0016 U mL−1 | [ |
| ZnO/AuNPs | GO paper | voltammetry | AFP | 0.0002–500 ng mL−1 | 0.08 pg mL−1 | [ |
| GOx/AgNPs | GCE | voltammetry | CEA | 0.001–50 ng mL−1 | 0.27 pg mL−1 | [ |
| ZnO/AgNPs | AuNRs paper | voltammetry | PSA | 0.004–60 ng mL−1 | 1.5 pg mL−1 | [ |
| Ag/AuNPs | GCE | voltammetry | CEA | 0.01–120 ng mL−1 | 8 pg mL−1 | [ |
| MCF/AuNPs | GCE | voltammetry | CEA | 0.05–1000 pg mL−1 | 0.024 pg mL−1 | [ |
| antibody/AuNPs | GCE | voltammetry | EGFR | 1–40 ng mL−1 | 50 pg mL−1 | [ |
| ferrocene/Fe3O4 | GCE | voltammetry | PSA | 0.01–40 ng mL−1 | 2 pg mL−1 | [ |
| CdSe QDs | GCE | voltammetry | GP73 | 20–5000 pM | 12 pM | [ |
LOD: lower limit of detection, AuNPs: gold nanoparticles, Th: thionine, PDA: poly(dopamine), GO: graphene oxide, GOx: glucose oxidase, MCF: mesoporous carob foam, QDs: quantum dots, GCE: glassy carbon electrode, AuE: gold electrode, ITO: indium tin oxide electrode, AuNR: gold nanorods, AFP: α-fetoprotein, EGFR: epidermal growth factor receptor, PSA: prostate-specific antigen, BRCA1: breast cancer susceptibility gene, CEA: carcinoembryonic antigen, HSP70: heat shock protein 70, IL-6: interleukin-6, CA-125: carbohydrate antigen-125, GP73: Golgi protein 73.
Figure 6(A) A calibration graph of aptamer sensor for the mucine. The changes in electron transfer resistance (∆ratio) were plotted vs. mucine concentration; (B) Nyquist plots of the aptamer sensor in the presence of mucine from 0.1 (a) to 2.0 U mL−1 (g). Reprinted from [76]. Copyright 2016 MDPI.
Figure 7Changes in drain current of an field effect transistors (FET) immunosensor for C-reactive protein (CRP). Inset shows a schematic illustration of the CRP sensor and its calibration graph. Reprinted with permission from [85]. Copyright 2013, Elsevier.
Figure 8Preparation of multi-walled carbon nanotube (MWCNT) labels modified with horseradish peroxidase (HRP) and Con A (A) and protocol for determining glycan expression on cancer cells (B). Reprinted with permission from [86]. Copyright 2013, Elsevier.
Figure 9DPV of QGY-7703 (A) and its calibration graphs obtained by using the MWCNT and MWCNT-free labels (B). Reprinted with permission from [86]. Copyright 2013, Elsevier.
Carbon nanotube-based biosensors for cancer biomarkers.
| Nanomaterials Used | Electrode | Transduction Method | Analyte | Detection Range | LOD | Ref. |
|---|---|---|---|---|---|---|
| SWCNTs | SPE | impedimetry | hCG | 0.01–100 ng mL−1 | - | [ |
| aptamer/MWCNTs | SPE | impedimetry | mucine | 0.1–2 U mL−1 | 0.02 U mL−1 | [ |
| PEDOT/CNTs | filter paper | amperometry | CEA | 2–15 ng mL−1 | 1 ng mL−1 | [ |
| MWCNTs | GCE | voltammetry | si-Gly | 10 fg·mL−1–50 ng mL−1 | 3 fg mL−1 | [ |
| MWCNTs/ZnO | GCE | voltammetry | CA125 | 0.001–1000 U mL−1 | 0.00113 U mL−1 | [ |
| aligned SWCNTs | PGE | amperometry | MMP-3 | 4–300 pg mL−1 | 4 pg mL−1 | [ |
| antibody/CNTs | FET | OPN | 0.001–1000 ng mL−1 | 1 pg mL−1 | [ | |
| SWCNTs | FET | CRP | 0.0001–100 μg mL−1 | 0.1 ng mL−1 | [ | |
| Con A/MWCNTs | GCE | voltammetry | QGY-7703 | 100–100,000 cells mL−1 | 40 cells mL−1 | [ |
| ferritin/MWCNTs | AuE | voltammetry | CA153 | 0.05–100 U mL−1 | 0.009 U mL−1 | [ |
| HRP/MWCNTs | AuE | voltammetry | PSA | 0.001–10 ng mL−1 | 0.4 pg mL−1 | [ |
| GOx/CNHs | GCE | voltammetry | AFP | 0.001–60 ng mL−1 | 0.33 pg mL−1 | [ |
| nano Au/CNHs | SPE | voltammetry | AFP | 0.1–1000 pg mL−1 | 0.07 pg mL−1 | [ |
SWCNTs: single-wall carbon nanotube, PEDOT: poly(3,4-ethylenedioxythiophene), SPE: screen-printed electrode, HRP: horseradish peroxidase, CNHs: carbon nanohorn, PGE: pyrolytic graphite electrode, FET: field effect transistor, V: gate voltage, I: drain current, V: drain voltage, hCG: human chorionic gonadotropin, si-Gly: α2,3-sialylated glycans, MMP-3: matrix metalloproteinase-3, OPN: osteopontin, CRP: C-reactive protein, QGY-7730: human liver cancer cell, CA153: carbohydrate antigen 15-3.
Figure 10Preparation of reduced graphene oxide (rGO) modified with thionine (TH) and Prussian blue (PB) (A) and CEA and AFP sensors based on rGO-modified electrodes (B). Reprinted with permission from [105]. Copyright 2014, Elsevier.
Graphene-based biosensors for cancer biomarkers.
| Nanomaterials Used | Electrode | Transduction Method | Analyte | Detection Range | LOD | Ref. |
|---|---|---|---|---|---|---|
| GO | SPGE | voltammetry | hCG | 5–500 pg mL−1 | 5 pg mL−1 | [ |
| GO | SPGE | impedimetry | hCG | 0.001–50 ng mL−1 | 0.286 pg mL−1 | [ |
| rGO | SPCE | voltammetry | AFP | 0.001–100 ng mL−1 | 1 pg mL−1 | [ |
| rGO | SPCE | voltammetry | CEA | 0.005–100 ng mL−1 | 5 pg mL−1 | [ |
| rGO | SPCE | voltammetry | CA125 | 0.001–100 ng mL−1 | 1 pg mL−1 | [ |
| rGO | SPCE | voltammetry | CA153 | 0.005–100 ng mL−1 | 5 pg mL−1 | [ |
| GCE | voltammetry | CA153 | 0.1–20 U mL−1 | 0.012 U mL−1 | [ | |
| multilayer GO | GO/SiC | impedimetry | hCG | 0.62–5.62 ng mL−1 | 0.62 ng mL−1 | [ |
| graphene | graphene foam | voltammetry | CEA | 0.1–750 ng mL−1 | 90 pg mL−1 | [ |
| thionine/GO | ITO | voltammetry | CEA | 0.01–300 ng mL−1 | 0.65 pg mL−1 | [ |
| PB/GO | ITO | voltammetry | AFP | 0.01–300 ng mL−1 | 0.885 pg mL−1 | [ |
| CoHCF/GO | GCE | voltammetry | PSA | 0.02–2 ng mL−1 | 0.01 ng mL−1 | [ |
| ZrO2/rGO | ITO | voltammetry | CYFRA-21-1 | 2–22 ng mL−1 | 0.122 ng mL−1 | [ |
| TB/GO-COOH | GCE | voltammetry | CEA | 0.5–60 ng mL−1 | 0.1 ng mL−1 | [ |
| PB/GO-COOH | GCE | voltammetry | AFP | 0.5–60 ng mL−1 | 0.05 ng mL−1 | [ |
| PB/AuNPs/GO | GCE | voltammetry | AFP | 0.01–100 ng mL−1 | 4.6 pg mL−1 | [ |
| CuS/GO | SPCE | voltammetry | AFP | 0.001–10 ng mL−1 | 0.5 pg mL−1 | [ |
rGO: reduced graphene oxide, PB: Prussian blue, CoHCF: cobalt hexacyanoferrate, TB: toluidine blue, GO-COOH: carboxylated graphene oxide, SPGE: screen-printed graphene electrode, SPCE: screen-printed carb electrode, SiC: silicon carbide, CYFRA-21-1: cytokeratin 19 fragment.